000300647 001__ 300647
000300647 005__ 20250427020303.0
000300647 0247_ $$2doi$$a10.1016/j.clnu.2025.04.017
000300647 0247_ $$2pmid$$apmid:40267517
000300647 0247_ $$2ISSN$$a0261-5614
000300647 0247_ $$2ISSN$$a1532-1983
000300647 0247_ $$2altmetric$$aaltmetric:176309980
000300647 037__ $$aDKFZ-2025-00858
000300647 041__ $$aEnglish
000300647 082__ $$a610
000300647 1001_ $$0P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780$$aSha, Sha$$b0$$eFirst author$$udkfz
000300647 245__ $$aReal-world evidence for an association of vitamin D supplementation with atherosclerotic cardiovascular disease in the UK Biobank.
000300647 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2025
000300647 3367_ $$2DRIVER$$aarticle
000300647 3367_ $$2DataCite$$aOutput Types/Journal article
000300647 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1745498279_21318
000300647 3367_ $$2BibTeX$$aARTICLE
000300647 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300647 3367_ $$00$$2EndNote$$aJournal Article
000300647 500__ $$a#EA:C070#LA:C070#
000300647 520__ $$aAtherosclerotic cardiovascular disease (ASCVD) remains a substantial healthcare burden. The Australian D-Health trial recently showed potential efficacy of vitamin D supplementation (VDS) in reducing major ASCVD events. Whether the efficacy could be translated into real-world effectiveness is unclear.Leveraging data from the UK Biobank, we used Cox regression with competing risk of all-cause mortality to assess the association of self-reported regular VDS (83.3 % from over-the-counter) and serum 25-hydroxyvitamin D (25[OH]D) levels with ASCVD as a composite endpoint and as separate endpoints including ischemic heart disease (IHD), cerebrovascular disease, peripheral arterial disease, and atherosclerotic disease.Among 409,822 study participants aged 40-69 years, 20.7 % were vitamin D deficient (25[OH]D < 30 nmol/L) and 34.4 % were vitamin D insufficient (25[OH]D 30-<50 nmol/L). Regular VDS was reported by 4.3 % of the study participants. During the follow-up of 15.9 years, 11.6 % of participants developed ASCVD. Compared to vitamin D sufficiency, vitamin D deficiency was associated with a significantly increased risk of the total ASCVD (hazard ratio [95 % confidence interval]: 1.10 [1.07-1.13]) and all separate ASCVD endpoints in the fully adjusted model with 48 covariates. Consistently, compared to non-users, VDS was associated with a reduced total ASCVD risk in the model fully adjusted for the 50 covariates (0.94[0.90-0.98]). Regarding the individual ASCVD disorders, VDS was associated with reduced IHD risk (0.90[0.86-0.96]).Self-reported regular VDS and being vitamin D sufficient were both associated with reduced ASCVD risk in real-world settings. For people with low 25(OH)D levels, regular VDS may be a beneficial strategy for ASCVD prevention.
000300647 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000300647 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300647 650_7 $$2Other$$a25-hydroxyvitamin D
000300647 650_7 $$2Other$$aAtherosclerotic cardiovascular disease
000300647 650_7 $$2Other$$aReal-world evidence
000300647 650_7 $$2Other$$aVitamin D supplement use
000300647 7001_ $$0P:(DE-He78)7089188e1b7bdb788ba48ba96f21df07$$aXie, Ruijie$$b1$$udkfz
000300647 7001_ $$0P:(DE-He78)35a941418cdcc6c595b7a8a19e355599$$aGwenzi, Tafirenyika$$b2$$udkfz
000300647 7001_ $$0P:(DE-He78)5a18ac1d8e95a59d44c072d0a7dba4b7$$aWang, Youqing$$b3$$udkfz
000300647 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$udkfz
000300647 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b5$$eLast author$$udkfz
000300647 773__ $$0PERI:(DE-600)2009052-3$$a10.1016/j.clnu.2025.04.017$$gVol. 49, p. 118 - 127$$p118 - 127$$tClinical nutrition$$v49$$x0261-5614$$y2025
000300647 909CO $$ooai:inrepo02.dkfz.de:300647$$pVDB
000300647 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000300647 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7089188e1b7bdb788ba48ba96f21df07$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000300647 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)35a941418cdcc6c595b7a8a19e355599$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000300647 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5a18ac1d8e95a59d44c072d0a7dba4b7$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000300647 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000300647 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000300647 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000300647 9141_ $$y2025
000300647 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-28$$wger
000300647 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN NUTR : 2022$$d2024-12-28
000300647 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000300647 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000300647 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000300647 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000300647 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-28
000300647 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000300647 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000300647 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN NUTR : 2022$$d2024-12-28
000300647 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000300647 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000300647 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPrimäre Krebsprävention$$x1
000300647 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000300647 980__ $$ajournal
000300647 980__ $$aVDB
000300647 980__ $$aI:(DE-He78)C070-20160331
000300647 980__ $$aI:(DE-He78)C120-20160331
000300647 980__ $$aUNRESTRICTED